Access to therapy is part of the protection of the constitutional order: Peter Bely spoke at the SPIEF session on intellectual property
14.07.2022
14.07.2022
Cefotaxime+Sulbactam replenished the antibacterial portfolio of Promomed Group. The advantage of the combination of cephalosporins with sulbactam is to expand the antimicrobial spectrum by affecting gram-negative bacterial strains, which makes it possible to widely use the antibiotic in medical practice.

The combination of cefotaxime and sulbactam is active against all microorganisms sensitive to cefotaxime. The drug has a wide spectrum of action. The drug has been shown to be highly effective in adults and children in the treatment of pneumonia, peritonitis, urinary tract infections, skin and soft tissues, as well as severe forms of infectious and inflammatory diseases.
Responding to the critical challenges of medicine, Promomed Group forms a portfolio of drugs aimed at treating socially significant diseases. By developing new drugs, the company offers patients effective and safe medicines due to the high quality of their substances, adaptability of production processes, and the highest quality control standards. The production of antibacterial drugs at the Promomed Group of Companies (Bihimik JSC) is carried out using full-cycle technology.
Cefotaxime + Sulbactam will be available in powder form for the preparation of a solution for intravenous and intramuscular administration at a dosage of 1000 mg + 500 mg, which corresponds to standard regimens of use.
Like most medicines produced by Promomed Group, this drug is included in the list of VED.
Stay informed
Stay informed
Get the most interesting news and publications first!
Sent successfully!
Press office
To request a press release or interview, please contact our press office